Home > Analytics > AUROBINDO PHARMA

AUROBINDO PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 524804     NSE : AUROPHARMA    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Jun 07,2023
Price(EOD): ₹ 672.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 39,395.92 Cr
Value of ₹ 1 Lac invested in AUROBINDO PHARMA
on Jun 07,2018 (price: ₹ 547.75)

₹ 1 L

₹ 1.23 L

1W : 1.5% 1M : 9.5% 1Y : 24.6%
COMMUNITY POLL
for AUROBINDO PHARMA
Please provide your vote to see the results
AUROBINDO PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks
Best 1M Momentum Mid Cap Stocks
Industry Peers & Returns1W1M1Y
AUROBINDO PHARMA 1.5% 9.5% 24.6%
SUN PHARMACEUTICAL INDUSTRIES 2.7% 5.9% 17.9%
DIVIS LABORATORIES 0.5% 4.8% 0.3%
CIPLA -0.4% 2.3% -1.5%
DR REDDYS LABORATORIES 2.6% -5.3% 7%
TORRENT PHARMACEUTICALS 1.5% 9.3% 27.1%
ABBOTT INDIA 1.3% -0.2% 18.8%
ZYDUS LIFESCIENCES 0.3% -1.9% 41.3%
ALKEM LABORATORIES 0.8% -5.8% 9.5%

FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA

 
Fundamentals Score
[ Q(TTM): Mar2023, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 AUROPHARMA is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF AUROBINDO PHARMA

 
Valuation Score
[As on : Jun 07,2023 ]

Ratio Consolidated
P/E
P/B
P/S
20.32
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,939.32 Cr
[Latest Qtr - Mar2023 - Consolidated Results ]

1.47
P/B Calculated based on Book Value of Rs 26,839.80 Cr
[Latest Year - Mar2023 - Consolidated Results ]

1.59
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 24,855.40 Cr
[Latest Qtr - Mar2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 23% undervalued companies ! Discover More →

FAIR VALUE OF AUROBINDO PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-13%
-28%
-8%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF AUROBINDO PHARMA


Insights 💡 AUROPHARMA is one of the top 48% companies with bullish price momentum currently! Discover More →

AUROBINDO PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF AUROBINDO PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.11
0.25
0.29
0.22
0.1
0.23
0.33
0.22
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF AUROBINDO PHARMA

Pledged Promoter Shares
17.9 %
As on : Mar2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF AUROBINDO PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
1.03%
5.01%
8.11%
4.1%
11.42%
2.85%
23.12%
-11.8%
QtrlyTrend
6
Latest Qtr: Mar2023
Quarterly Result Analysis →


AUROBINDO PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 3.2% 5.1% 10%
S&P BSE MIDSMALLCAP 2.9% 6.7% 19.4%
S&P BSE 400 MIDSMALLCAP 2.5% 6% 19.2%
S&P BSE MID CAP 2.4% 6.4% 20%
S&P BSE 150 MIDCAP 2.1% 5.7% 18.6%
NSE Indices1W1M1Y
NIFTY HEALTHCARE 3.2% 4.9% 10.2%
NIFTY PHARMA 2.9% 3% 4.8%
NIFTY MID SMALL400 2.6% 6.3% 20%
NIFTY MIDCAP150 2.2% 5.9% 21.1%
NIFTY500 MULTICAP 50:25:25 2% 4.8% 15.5%

You may also like the below Video Courses


FAQ about AUROBINDO PHARMA


Is AUROBINDO PHARMA good for long term investment?

As on Jun 07,2023, the Fundamentals of AUROBINDO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AUROBINDO PHARMA UnderValued or OverValued?

As on Jun 07,2023, AUROBINDO PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of AUROBINDO PHARMA ?

As on Jun 07,2023, the Intrinsic Value of AUROBINDO PHARMA is Rs. 776.27 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 776.27
Fair Value [Median EV / Sales Model] : Rs. 932.03
Fair Value [Median Price / Sales Model] : Rs. 727.07
Estimated Median Fair Value of AUROBINDO PHARMA : Rs. 776.27

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is AUROBINDO PHARMA trading at a Premium or Discount?

As on Jun 07,2023, AUROBINDO PHARMA is trading at a Discount of -13% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].